News
Rznomics applies for phase 1 and 2 clinical trials in Korea for malignant glioblastoma
-
- 작성자
- 관리자
-
- 날짜
- 2023-01-05
Attempt to extend RZ-001 indication Rznomics announced on January 4 that it applied to the Ministry of Food and Drug Safety for phase 1 and 2 clinical trials for malignant glioblastoma (brain cancer) of "RZ-001", a new anticancer drug candidate.
RZ-001 was approved by the Ministry of Food and Drug Safety and the U.S. Food and Drug Administration (FDA) last year and is undergoing clinical trials. Malignant glioblastoma is an incurable disease with a 5-year survival rate of less than 3 percent and no clear treatment yet. Immuno-cancer drugs also showed no therapeutic effect, so a new mechanism of treatment is urgently needed.
Rznomics has a technology that removes target RNA based on RNA trans-splicing ribozyme and expresses the desired gene. RZ-001 is an adenovirus that carries ribonucleic acid substituent. It targets telomerase (hTERT) RNA that is specific to cancer cells and expresses genes that induce anticancer action. It is said that telomerase targeted by RZ-001 can be applied to various carcinomas because it is expressed in most cancer cells.
Rznomics is pushing to expand its indications to other intractable cancers, starting with hepatocellular carcinoma undergoing clinical trials and this malignant glioblastoma. It is also developing treatments in various fields using platform technologies such as Alzheimer's, hereditary retinal pigmentation, and retinal syndrome as well as anticancer drugs.
Seong-wook Lee, CEO of Rznomics, said, "The candidate materials under development are entering clinical trials as planned. We will do our best to speed up the progress of clinical trials and quickly provide new treatment opportunities to patients suffering from incurable diseases."
RZ-001 was approved by the Ministry of Food and Drug Safety and the U.S. Food and Drug Administration (FDA) last year and is undergoing clinical trials. Malignant glioblastoma is an incurable disease with a 5-year survival rate of less than 3 percent and no clear treatment yet. Immuno-cancer drugs also showed no therapeutic effect, so a new mechanism of treatment is urgently needed.
Rznomics has a technology that removes target RNA based on RNA trans-splicing ribozyme and expresses the desired gene. RZ-001 is an adenovirus that carries ribonucleic acid substituent. It targets telomerase (hTERT) RNA that is specific to cancer cells and expresses genes that induce anticancer action. It is said that telomerase targeted by RZ-001 can be applied to various carcinomas because it is expressed in most cancer cells.
Rznomics is pushing to expand its indications to other intractable cancers, starting with hepatocellular carcinoma undergoing clinical trials and this malignant glioblastoma. It is also developing treatments in various fields using platform technologies such as Alzheimer's, hereditary retinal pigmentation, and retinal syndrome as well as anticancer drugs.
Seong-wook Lee, CEO of Rznomics, said, "The candidate materials under development are entering clinical trials as planned. We will do our best to speed up the progress of clinical trials and quickly provide new treatment opportunities to patients suffering from incurable diseases."
- 본사경기도 용인시 수지구 죽전로 152, 단국대학교 소프트웨어ICT관 327호
- TEL. 031-706-8730
- FAX. 031-8018-8734
- E_mailrznomics@rznomics.com
- 기업부설연구소 및 판교지점경기도 성남시 분당구 판교로 253, 판교이노밸리 C동 801호(판교지점), 803호(기업부설연구소)
- TEL. 031-706-8730
Copyright(C) 2019 Rznomics. All Rights Reserved.
